MiR-27b-regulated TCTP as a novel plasma biomarker for oral cancer: From quantitative proteomics to post-transcriptional study

Journal of Proteomics

Volumn 77, Issue , 2012, Pages 154-166

  Lo, Wan Yu ^a,b,c   Wang, Huang Joe ^b,d   Chiu, Chih Wei ^e   Chen, Sung Fang ^e  

^a CHINA MEDICAL UNIVERSITY   (Taiwan)

^b CHINA MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

^c NATIONAL CHUNG HSING UNIVERSITY   (Taiwan)

^d CHINA MEDICAL UNIVERSITY   (Taiwan)

^e NATIONAL TAIWAN NORMAL UNIVERSITY   (Taiwan)

Author keywords

ITRAQ; MiR 27b; Oral cancer; Quantitative proteomic analysis; TCTP; Translationally controlled tumor protein

Indexed keywords

ALPHA6 INTEGRIN; BINDING PROTEIN; BIOLOGICAL MARKER; CALCIUM BINDING PROTEIN 39 LIKE PROTEIN; EPIDERMAL GROWTH FACTOR RECEPTOR; MICRORNA; MICRORNA 186; MICRORNA 19A; MICRORNA 19B; MICRORNA 203; MICRORNA 27A; MICRORNA 27B; MICRORNA 377; ONCOPROTEIN; ORNITHINE OXOACID AMINOTRANSFERASE; RAS GTPASE ACTIVATING PROTEIN BINDING PROTEIN 1; TRANSLATIONALLY CONTROLLED TUMOR PROTEIN; UNCLASSIFIED DRUG;

ANALYTIC METHOD; ARTICLE; CANCER CELL CULTURE; CANCER TISSUE; CB39L GENE; CLINICAL ARTICLE; CONTROLLED STUDY; DIAGNOSTIC VALUE; EARLY DIAGNOSIS; EGFR GENE; FUNCTIONAL PROTEOMICS; G3BP1 GENE; GENETIC TRANSCRIPTION; HUMAN; HUMAN TISSUE; IN VITRO STUDY; ISOBARIC TAG FOR RELATIVE AND ABSOLUTE QUANTIFICATION; ITGA6 GENE; LIQUID CHROMATOGRAPHY; MOUTH SQUAMOUS CELL CARCINOMA; NUCLEOTIDE SEQUENCE; OAT GENE; PREDICTION; PRIORITY JOURNAL; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION; SCREENING; TANDEM MASS SPECTROMETRY; TPT1 GENE; TRANSLATION REGULATION;

CELL LINE, TUMOR; FEMALE; GENE EXPRESSION REGULATION; HUMANS; MALE; MICRORNAS; MOUTH NEOPLASMS; NEOPLASM PROTEINS; PROTEOMICS; RNA, NEOPLASM; TRANSCRIPTION, GENETIC; TUMOR MARKERS, BIOLOGICAL;

EID: 84870394042     PISSN: 18743919     EISSN: 18767737     Source Type: Journal    
DOI: 10.1016/j.jprot.2012.07.039     Document Type: Article

References (48)

1. Jemal A., Bray F., Center M.M., Ferlay J., Ward E., Forman D. Global cancer statistics. CA Cancer J Clin 2011, 61(2):69-90.
2. Seiwert T.Y., Cohen E.E. State-of-the-art management of locally advanced head and neck cancer. Br J Cancer 2005, 92(8):1341-1348.
3. Ho P.S., Ko Y.C., Yang Y.H., Shieh T.Y., Tsai C.C. The incidence of oropharyngeal cancer in Taiwan: an endemic betel quid chewing area. J Oral Pathol Med 2002, 31(4):213-219.
4. Chen Y.J., Chang J.T., Liao C.T., Wang H.M., Yen T.C., Chiu C.C., et al. Head and neck cancer in the betel quid chewing area: recent advances in molecular carcinogenesis. Cancer Sci 2008, 99(8):1507-1514.
5. Turhani D., Krapfenbauer K., Thurnher D., Langen H., Fountoulakis M. Identification of differentially expressed, tumor-associated proteins in oral squamous cell carcinoma by proteomic analysis. Electrophoresis 2006, 27(7):1417-1423.
6. Gstaiger M., Jordan R., Lim M., Catzavelos C., Mestan J., Slingerland J., et al. Skp2 is oncogenic and overexpressed in human cancers. Proc Natl Acad Sci U S A 2001, 98(9):5043-5048.
7. Huang X., Gollin S.M., Raja S., Godfrey T.E. High-resolution mapping of the 11q13 amplicon and identification of a gene, TAOS1, that is amplified and overexpressed in oral cancer cells. Proc Natl Acad Sci U S A 2002, 99(17):11369-11374.
8. Sugimura T., Kumimoto H., Tohnai I., Fukui T., Matsuo K., Tsurusako S., et al. Gene-environment interaction involved in oral carcinogenesis: molecuar epidemiological study for metabolic and DNA repair gene polymorphisms. J Oral Pathol Med 2006, 35(1):11-18.
9. Kallioniemi O. Medicine: profile of a tumour. Nature 2004, 428(6981):379-382.
10. Geho D.H., Petricoin E.F., Liotta L.A. Blasting into the microworld of tissue proteomics: a new window on cancer. Clin Cancer Res 2004, 10(3):825-827.
11. Garbis S.D., Tyritzis S.I., Roumeliotis T., Zerefos P., Giannopoulou E.G., Vlahou A., et al. Search for potential markers for prostate cancer diagnosis, prognosis and treatment in clinical tissue specimens using amine-specific isobaric tagging (iTRAQ) with two-dimensional liquid chromatography and tandem mass spectrometry. J Proteome Res 2008, 7(8):3146-3158.
12. Wu W.W., Wang G., Baek S.J., Shen R.F. Comparative study of three proteomic quantitative methods, DIGE, cICAT, and iTRAQ, using 2D gel- or LC-MALDI TOF/TOF. J Proteome Res 2006, 5(3):651-658.
13. Ross P.L., Huang Y.N., Marchese J.N., Williamson B., Parker K., Hattan S., et al. Multiplexed protein quantitation in Saccharomyces cerevisiae using amine-reactive isobaric tagging reagents. Mol Cell Proteomics 2004, 3(12):1154-1169.
14. Ralhan R., Desouza L.V., Matta A., Chandra T.S., Ghanny S., Dattagupta S., et al. iTRAQ-multidimensional liquid chromatography and tandem mass spectrometry-based identification of potential biomarkers of oral epithelial dysplasia and novel networks between inflammation and premalignancy. J Proteome Res 2009, 8(1):300-309.
15. Lewis B.P., Burge C.B., Bartel D.P. Conserved seed pairing, often flanked by adenosines, indicates that thousands of human genes are microRNA targets. Cell 2005, 120(1):15-20.
16. Hsieh H.C., Chen Y.T., Li J.M., Chou T.Y., Chang M.F., Huang S.C. Protein profilings in mouse liver regeneration after partial hepatectomy using iTRAQ technology. J Proteome Res 2009, 8(2):1004-1013.
17. Farh K.K., Grimson A., Jan C., Lewis B.P., Johnston W.K., Lim L.P., et al. The widespread impact of mammalian MicroRNAs on mRNA repression and evolution. Science 2005, 310(5755):1817-1821.
18. Cullen B.R. Transcription and processing of human microRNA precursors. Mol Cell 2004, 16(6):861-865.
19. Calin G.A., Croce C.M. MicroRNA signatures in human cancers. Nat Rev Cancer 2006, 6(11):857-866.
20. Gomes C.C., Gomez R.S. MicroRNA and oral cancer: future perspectives. Oral Oncol 2008, 44(10):910-914.
21. Lima R.T., Busacca S., Almeida G.M., Gaudino G., Fennell D.A., Vasconcelos M.H. MicroRNA regulation of core apoptosis pathways in cancer. Eur J Cancer 2011, 47(2):163-174.
22. Kouwenhove M.V., Kedde M., Agami R. MicroRNA regulation by RNA-binding proteins and its implications for cancer. Nat Rev Cancer 2011, 11(9):644-656.
23. Uesugi A., Kozaki K., Tsuruta T., Furuta M., Morita K., Imoto I., et al. The tumor suppressive microRNA miR-218 targets the mTOR component Rictor and inhibits AKT phosphorylation in oral cancer. Cancer Res 2011, 71(17):5765-5778.
24. Hanash S.M., Pitteri S.J., Faca V.M. Mining the plasma proteome for cancer biomarkers. Nature 2008, 452(7187):571-579.
25. Faca V.M., Song K.S., Wang H., Zhang Q., Krasnoselsky A.L., Newcomb L.F., et al. A mouse to human search for plasma proteome changes associated with pancreatic tumor development. PLoS Med 2008, 5(6):953-967.
26. Lo W.Y., Tsai M.H., Tsai Y., Hua C.H., Tsai F.J., Huang S.Y., et al. Identification of over-expressed proteins in oral squamous cell carcinoma (OSCC) patients by clinical proteomic analysis. Clin Chim Acta 2007, 376(1-2):101-107.
27. Chen W.T., Chang S.C., Ke T.W., Chiang H.C., Tsai F.J., Lo W.Y. Identification of biomarkers to improve diagnostic sensitivity of sporadic colorectal cancer in patients with low preoperative serum carcinoembryonic antigen by clinical proteomic analysis. Clin Chim Acta 2011, 412(7-8):636-641.
28. Betel D., Koppal A., Agius P., Sander C., Leslie C. Comprehensive modeling of microRNA targets predicts functional non-conserved and non-canonical sites. Genome Biol 2010, 11:R90.
29. Cho W.C. Contribution of oncoproteomics to cancer biomarker discovery. Mol Cancer 2007, 6:25.
30. Tanke H.J. Genomics and proteomics: the potential role of oral diagnostics. Ann N Y Acad Sci 2007, 1098:330-334.
31. Najam-ul-Haq M., Rainer M., Trojer L., Feuerstein I., Vallant R.M., Huck C.W., et al. Alternative profiling platform based on MELDI and its applicability in clinical proteomics. Expert Rev Proteomics 2007, 4(4):447-452.
32. Zieske L.R. A perspective on the use of iTRAQ reagent technology for protein complex and profiling studies. J Exp Bot 2006, 57(7):1501-1508.
33. DeSouza L.V., Grigull J., Ghanny S., Dubé V., Romaschin A.D., Colgan T.J., et al. Endometrial carcinoma biomarker discovery and verification using differentially tagged clinical samples with multidimensional liquid chromatography and tandem mass spectrometry. Mol Cell Proteomics 2007, 6(7):1170-1182.
34. Chen L.H., Tsai K.L., Chen Y.W., Yu C.C., Chang K.W., Chiou S.H., et al. MicroRNA as a novel modulator in head and neck squamous carcinoma. J Oncol 2010, 2010:135632.
35. Jung J., Kim H.Y., Kim M., Sohn K., Kim M., Lee K. Translationally controlled tumor protein induces human breast epithelial cell transformation through the activation of Src. Oncogene 2011, 30(19):2264-2274.
36. Cariati M., Naderi A., Brown J.P., Smalley M.J., Pinder S.E., Caldas C. Alpha-6 integrin is necessary for the tumourigenicity of a stem cell-like subpopulation within the MCF7 breast cancer cell line. Int J Cancer 2008, 122(2):298-304.
37. Zhang P.Y., Zhang W.G., He A.L., Wang J.L., Li W.B. Identification and functional characterization of the novel acute monocytic leukemia associated antigen MLAA-34. Cancer Immunol Immunother 2009, 58(2):281-290.
38. Calin G.A., Croce C.M. MicroRNA signatures in human cancers. Nat Rev Cancer 2006, 6(11):857-866.
39. Komatsu S., Ichikawa D., Takeshita H., Tsujiura M., Morimura R., Nagata H., et al. Circulating microRNAs in plasma of patients with oesophageal squamous cell carcinoma. Br J Cancer 2011, 105(1):104-111.
40. Kozaki K., Imoto I., Mogi S., Omura K., Inazawa J. Exploration of tumor-suppressive microRNAs silenced by DNA hypermethylation in oral cancer. Cancer Res 2008, 68(7):2094-2105.
41. Tsuchiya Y., Nakajima M., Takagi S., Taniya T., Yokoi T. MicroRNA regulates the expression of human cytochrome P450 1B1. Cancer Res 2006, 66(18):9090-9098.
42. Chen S.H., Wu P.S., Chou C.H., Yan Y.T., Liu H., Weng S.Y., Yang-Yen H.F. A knockout mouse approach reveals that TCTP functions as an essential factor for cell proliferation and survival in a tissue- or cell type-specific manner. Mol Biol Cell 2007, 18(7):2525-2532.
43. Tuynder M., Fiucci G., Prieur S., Lespagnol A., Géant A., Beaucourt S., Duflaut D., Besse S., Susini L., Cavarelli J., Moras D., Amson R., Telerman A. Translationally controlled tumor protein is a target of tumor reversion. Proc Natl Acad Sci U S A 2004, 101(43):15364-15369.
44. Tuynder M., Susini L., Prieur S., Besse S., Fiucci G., Amson R., Telerman A. Biological models and genes of tumor reversion: cellular reprogramming through tpt1/TCTP and SIAH-1. Proc Natl Acad Sci U S A 2002, 99(23):14976-14981.
45. Jung J., Kim H.Y., Kim M., Sohn K., Kim M., Lee K. Translationally controlled tumor protein induces human breast epithelial cell transformation through the activation of Src. Oncogene 2011, 30(19):2264-2274.
46. Zou G.M. Cancer initiating cells or cancer stem cells in the gastrointestinal tract and liver. J Cell Physiol 2008, 217(3):598-604.
47. Wang Y., Rathinam R., Walch A., Alahari S.K. ST14 (suppression of tumorigenicity 14) gene is a target for miR-27b, and the inhibitory effect of ST14 on cell growth is independent of miR-27b regulation. J Biol Chem 2009, 284(34):23094-23106.
48. Peric D., Chvalova K., Rousselet G. Identification of microprocessor-dependent cancer cells allows screening for growth-sustaining micro-RNAs. Oncogene 2011, 1-10.